Not all people with CLL demand therapy. Despite all current innovations, the iwCLL nevertheless endorses watchful observation for individuals with asymptomatic disease.86 This advice is based on at the least two randomized trials comparing observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).. intolera